

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b> Application Number 10/785,497 Filing Date February 24, 2004 First Named Inventor Mark W. Becker et al. Art Unit 1657 Examiner Name P.C. Martin Attorney Docket Number 249.P2	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>			
Sheet	1	of	2

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figure Appear	†*
		Country Code <sup>2</sup> Number* Kind Code <sup>3</sup> (if known)	MM-DD-YYYY			
	BA	WO-0208241	01-31-2002	Gilead Sciences Inc et al.		
	BB	WO-9200988	01-23-1992	Bodor Nicholas S		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER. Initial if reference coincides, whether or not citation is in conformance with MPPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those applications(s) which are marked with an single asterisk (\*) next to the Cite NO. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IFW. \*\* CITE NO.: Those document(s) which are marked with an double asterisk (\*\*) next to the Cite NO. are not supplied after they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 102(b). \* Applicant's unique citation designation number must be included in the application for the purpose of identification of the document cited. \* Enter Office of the Commissioner of Patents and Trademark (WFO/PTO Standard St.3.). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WFO/PTO Standard St.16 if possible. \* Applicant is to place a check mark here if English language translation is attached.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b> Application Number <b>10/785,497</b> Filing Date <b>February 24, 2004</b> First Named Inventor <b>Mark W. Becker et al.</b> Art Unit <b>1657</b> Examiner Name <b>P. C. Martin</b> Attorney Docket Number <b>249.P2</b>	
Sheet	2	2	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	Beach et al. (1998) "Chemotherapeutic agents for human immunodeficiency virus infection: Mechanism of action, pharmacokinetics, metabolism, and adverse reactions," <i>Clinical Therapeutics</i> 20(1):2-25	
	CB	CAMP, N.P. et al. (1995) "Synthesis of Peptide Analogues Containing Phosphonamide Methyl Ester Functionality: HIV-1 Proteinase Inhibitors Possessing Unique Cell Uptake Properties."	
	CC	Cihlar et al. (2006) "Suppression of HIV-1 Protease Inhibitor Resistance by Phosphonate-mediated solvent anchoring," <i>Journal of Molecular Biology</i> 363(3):635-647	
	CD	Eddershaw et al. (2000) "ADME/PK as part of a rational approach to drug discovery" <i>Drug Discovery Today</i> 5(9):409-414	
	CE	FRANCHETTI, P., et al. (1998) "Potent and Selective Inhibitors of Human Immunodeficiency Virus Protease Structurally Related to L-94,746," <i>Antiviral Chemistry &amp; Chemotherapy</i> 9(4):303-309	
	CF	GULICK (2003) "New Antiviral Drugs," <i>Clinical Microbiology and Infectious Diseases</i> 9:186-193	
	CG	HOLY (2003) "Phosphonothioalkyl Analogs of Nucleotides," <i>Current Pharmaceutical Design</i> 9:2567-2592	
	CH	Hoggard et al. (2002) "Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules," <i>Current Opinion in Infectious Diseases</i> 15(1):3-8	
	CI	Kiso et al. (1999) "Design of small peptidomimetic HIV-1 Protease Inhibitors and Prodrug Forms," 6(5/6):275-281	
	CJ	Krise et al. (1996) "Prodrugs of Phosphates, Phosphonates, and Phosphinates," <i>Advanced Drug Delivery Reviews</i> 19(2):287-310	
	CK	Kubota et al. (1998) "Novel inhibitory effects of gamma-glutamylcysteine ethyl ester against human immunodeficiency virus type 1 production and propagation," <i>Antimicrobial Agents and Chemotherapy</i> 42(5):1200-1206	
	CL	Lee et al. (2002) "In Vivo and In Vitro Characterization of GS 7340, an isopropylalaninyl phenyl ester prodrug of Tenofovir: selective intracellular activation of GS 7340 leads to preferential distribution in lymphatic tissues. 9th Conference of Retroviruses and Opportunistic Infections, Abstract No. 3847	
	CM	Robbins et al. (1998) "Anti-Human Immunodeficiency Virus Activity and Cellular Metabolism of A Potential Prodrug of the Acyclic Nucleoside Phosphonate 9-R-(2-Phosphonomethoxypropyl) Adenine (PMPA), Bis(Isopropoxyloxymethylcarbonyl) PMPA" <i>Antimicrobial Agents and Chemotherapy</i> 42(3):612-617	
	CN	Zimra et al. (2000) "Uptake of pivaloyloxymethyl butyrate into leukemic esterase-catalyzed hydrolysis," <i>Journal of Cancer Research and Clinical Oncology</i> 126(12):693-698	

Examiner Signature	Date Considered	
--------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*\* CITE NO.: These document(s) which are marked with an asterisk (\*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant to place a check mark here if English language Translation is attached.